Author

Arturo Olguin

Observed names: A. Olguin, Arturo Olguín, Olguin, Arturo

Institution: Stemline Therapeutics (United States)

Observed institution: Stemline Therapeutics (United States)

OpenAlex ID: A5026319643

Identification of Peptide Sequences Specific for Serum Antibodies from Human Papillomavirus-Infected Patients Using Phage Display Libraries

2001 · H. Santamaria, K. Manoutcharian, et al. · Clinical Immunology · 17

Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML)

2018 · Mrinal M. Patnaik, Haris Ali, et al. · Blood · 15

Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis

2018 · Naveen Pemmaraju, Vikas Gupta, et al. · Blood · 9

Interim results from a phase 1 trial of SL-801, a novel XPO-1 inhibitor, in patients with advanced solid tumors.

2018 · Judy Sing-Zan Wang, Minal A. Barve, et al. · Journal of Clinical Oncology · 2

Decreased TXNRD1 is associated with resistance to tagraxofusp in blastic plasmacytoid dendritic cell neoplasms, as seen in phase II

2026 · Hannah C. Beird, Sankaranarayanan Kannan, et al. · Leukemia · 1

A High Throughput Quantitative Seroproteomics Analysis of Multiple Myeloma Patients on Tagraxofusp Therapy Identifies Novel Cytokine-Assisted Mechanism of Action

2020 · Arghya Ray, Yan Song, et al. · Blood · 1

Biological correlates to support a clinical role for tagraxofusp, a novel targeted therapy directed to CD123, in combination with pomalidomide and dexamethasone, to target plasmacytoid dendritic cells in poor-risk patients with multiple myeloma.

2020 · Dharminder Chauhan, Arghya Ray, et al. · Journal of Clinical Oncology · 1

Abstract B038: Multi-omic Analyses in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Tagraxofusp

2026 · Hannah C. Beird, Sankaranarayanan C. Kannan, et al. · Cancer Research

Novel Cytokine-Mediated Mechanism of Action Identified By Quantitative Seroproteomics in Multiple Myeloma Patients Treated with Tagraxofusp, a Novel CD123-Directed Targeted Therapy

2021 · Arghya Ray, Clifton C. Mo, et al. · Blood

P-086: Quantitative seroproteomics analysis of Multiple Myeloma patients treated with Tagraxofusp, a novel CD123-directed targeted therapy, identifies novel cytokine-mediated mechanism of action

2021 · Arghya Ray, Ting Du, et al. · Clinical Lymphoma Myeloma & Leukemia

Interim results from a phase I trial of SL-801: A novel XPO-1 inhibitor, in patients with advanced solid tumors

2018 · T.M. Bauer, M. Barve, et al. · Annals of Oncology

Ongoing phase 1 trial of SL-801, a novel XPO-1 inhibitor, in patients with advanced solid tumors; Interim results

2017 · J. Wang, J. Nemunaitis, et al. · Annals of Oncology

Uso de antibióticos en la solución de irrigación durante la cirugía de catarata

2015 · Antonio Méndez Noble, Arturo Olguín, et al. · Revista Mexicana de Oftalmología

A Review of Genetic Transfer Therapy Trials from a Regulatory Perspective for the Scientific Understanding

2013 · Olguin, Arturo

Works count: 14

Citation count: 46

H-index: 3

I10-index: 2